Login to Your Account


REBIOTIX CEO SAYS MOMENTUM TO CONTINUE

Seres Therapeutics Inc.'s stock-joltingly failed phase II study with SER-109 was not the first or only placebo-controlled microbiome trial against recurrent CDI, and better news will roll out during scientific sessions this fall from Rebiotix Inc., with RBX2660.

more »


Opinion


Partners in Focus